Business Wire

Aqara Announces Global Availability of Smart Lock U200

Share

Aqara, a global leader and pioneer in IoT, today announced the official launch of the highly anticipated Smart Lock U200. Designed as a retrofit, keyless solution for home access management, the U200 lock offers unparalleled convenience, advanced security features, and seamless interoperability across smart home ecosystems and devices thanks to its native Matter compatibility.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240709404547/en/

Aqara Smart Lock U200 (Photo: Business Wire)

The Aqara Smart Lock U200 brings a modern keyless lifestyle to a broad array of homeowners and renters, and provides multiple secure door entry options, including Apple home keys, which allow iOS users to unlock effortlessly by tapping a compatible iPhone or Apple Watch. The U200 distinguishes itself as one of the first Matter-over-Thread locks to support home key unlocking and is also one of the first retrofit smart locks to feature Apple home key.

Other unlocking methods of the Smart Lock U200 include:

  • Fingerprint recognition: Fast and secure access with the high-precision fingerprint reader.
  • PIN codes: Personalized codes can be entered on the included, pre-paired wireless keypad. Moreover, Aqara Home users can manage guess access easily with not only periodic passwords but also one-time passwords that can be remotely created, shared, and used even when the lock is disconnected from any platforms.
  • Mobile apps and voice assistants: Remote control via Aqara Home, Alexa, Apple Home/Siri, Google Home/Google Assistant, SmartThings, Home Assistant, and more1.
  • Aqara NFC cards: Quick and easy unlocking using Aqara’s NFC key fobs2.
  • Traditional keys: emergency access with the original keys.

The U200 lock stands out with its hassle-free retrofit design, allowing homeowners and renters to upgrade their existing locks - such as Euro mortise locks and US deadbolt locks - without the need to change keys or modify the door structure. This lock provides an instant smart update to most homes and is suitable for DIY installation, as attaching the U200 over the existing lock is simple and requires no tool apart from a screwdriver.

Security is a top priority with the Smart Lock U200. It features advanced encryption to protect against hacking, a tamper alarm on the wireless keypad, and an auto-lock function that secures the door automatically after a set period. Additionally, the U200 provides real-time notifications to keep users informed about their home’s security status.

The U200 retains many popular features of the previous Aqara locks, such as local and encrypted storage of sensitive data like fingerprints and passwords, anti-peep PIN code protection, Do-Not-Disturb mode, Passage mode, and Night Latch mode3. Furthermore, it adds thoughtful features like quiet unlock mode to minimize the noise level, pull spring feature for handle-less or inward-opening doors, as well as turn-to-lock and turn-to-unlock functions.

Built upon the energy-efficient Thread protocol, the U200 lock is designed for extended use. The lock runs on rechargeable Li-Ion batteries and boasts a battery life of up to 6 months between each charge. Additionally, the IPX5-rated wireless keypad is operable with AAA batteries or existing doorbell wiring, which allows for uninterrupted usage4.

The Smart Lock U200 is now available at Aqara’s Amazon brand stores throughout North America (US, Canada) and Europe (France, Germany, Italy, Netherlands, Poland, Spain, UK), as well as through select Aqara retailers worldwide.

The U200 lock is compatible with Euro mortise locks with Emergency Function, and supports various cylinders including EU profile cylinders, select Scandi profile cylinders and UK oval cylinders. An Emergency Function enables the cylinder to be unlocked from the outside using a key, even if another key is already inserted on the inside. Adjustable cylinders are sold separately by Aqara. The U200 is also compatible with single-cylinder deadbolt locks.

For more information on the U200 lock and its compatibility, please visit our website.

  1. A Matter controller with Thread Border Router functionality is required to connect the Smart Lock U200 to any third-party Matter-enabled system.
  2. Aqara NFC card is available in-box with the Smart Lock U200 Kit or sold separately.
  3. Some of these features may not be available at the time of launch, and will be added via subsequent OTA updates.
  4. The 6-month battery life is based on the assumption of 8 cycles of unlocking and locking per day. To operate the wireless keypad with the existing doorbell wiring, a 12V-24V AC/DC power supply is required.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240709404547/en/

Contacts

For Media Inquiries:
media@aqara.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye